Challenges, benefits, case study
|
|
- Brice Martin
- 5 years ago
- Views:
Transcription
1 hallenges, benefits, case study
2 Pharmaceutical development phases overview The new paradigm for development: Quality by Design (QbD) hallenges Benefits ase study losure and Q&A»»»»»» D. eriani Meet MINITAB, Milano 2/04/206 2
3 D. eriani Meet MINITAB, Milano 2/04/206 3
4 D. eriani Meet MINITAB, Milano 2/04/206 Pharmaceutical development phases MEDIAL NEED MARKET ANALYSIS 4
5 Pharmaceutical development phases D. eriani Meet MINITAB, Milano 2/04/206 5
6 D. eriani Meet MINITAB, Milano 2/04/206 6
7 you. The need for inspection results from excessive variability in the process. The disease is the variability. easing dependence on inspection means you must understand your processes so well that you can predict the quality of their output from upstream activities and measurements. To accomplish this you must have a thorough understanding of the sources of variation in your processes and Pharmaceutical development phases Depending on inspection is like treating a symptom while the disease is killing then work toward reducing the variation. easing dependence on inspection forces you to reduce variability D. eriani Meet MINITAB, Milano 2/04/206 7
8 Pharmaceutical Development Quality Risk Management Pharmaceutical Quality System Development and Manufacture of Drug Substances (chemical/biological entities): in progress - Q8: - Q9: - Q0: - Q: Develop a harmonised pharmaceutical quality system applicable across the lifecycle of the product emphasizing an integrated approach to quality risk management and science I: International onference of armonization D. eriani Meet MINITAB, Milano 2/04/206 8
9 The aim of pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the intended performance of the product. The information and knowledge gained from pharmaceutical development studies and manufacturing experience provide scientific understanding to support the establishment of the design space, specifications, and manufacturing controls. Information from pharmaceutical development studies can be a basis for quality risk management. It is important to recognize that quality cannot be tested into products, i.e., quality should be built in by design D. eriani Meet MINITAB, Milano 2/04/206 9
10 » Risk: defined as the combination of the probability of occurrence of harm, the severity and the detectability of that harm» Management: Systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle. D. eriani Meet MINITAB, Milano 2/04/206 Pharmaceutical development phases» Quality: Degree to which a set of inherent properties of a product, system or process fulfills requirements (in vivo efficacy and safety, formulation stability, patient compliance...) 0
11 D. eriani Meet MINITAB, Milano 2/04/206 Pharmaceutical development phases Quality Target Product Profile (QTPP) Quality Risk Management (QRM) Design of Experiments (DoE) ritical Quality Attribute (QA) Knowledge Management (KM) ritical Process Parameter (PP) ontrol Strategy (S) Process Analytical Technology (PAT) Lifecycle Management (LM) ontinuous Improvement (I)
12 Pharmaceutical development phases D. eriani Meet MINITAB, Milano 2/04/206 2
13 Pharmaceutical development phases D. eriani Meet MINITAB, Milano 2/04/206 dc 3
14 D. eriani Meet MINITAB, Milano 2/04/206 4
15 D. eriani Meet MINITAB, Milano 2/04/206 5
16 Factors that influence safety and efficacy: Absorption Distribution Metabolism Excretion Protein binding D. eriani Meet MINITAB, Milano 2/04/206 6
17 Organizational changes (cross functional team, ad hoc department creation, ) Need for employees training Need for new hardware and software Need for a change of mind of the upper managment D. eriani Meet MINITAB, Milano 2/04/206 7
18 D. eriani Meet MINITAB, Milano 2/04/206 8
19 More innovation= intellectual property Reduced time to market More efficient production process = less batch failure. More flexible regulatory approaches Reduced time to approval Reduced inspection frequencies D. eriani Meet MINITAB, Milano 2/04/206 9
20 onsistent efficacy onsistent safety onsistent quality Reduced sale price? D. eriani Meet MINITAB, Milano 2/04/206 20
21 D. eriani Meet MINITAB, Milano 2/04/206 2
22 Pharmaceutical development phases D. eriani Meet MINITAB, Milano 2/04/206 22
23 API content: Impurities profile: topical immediate liquid stratum corneum permeation no unpleasant smell good spreadability good spraying properties % w/w unknown 0.% specified known 0.5 to % 24 months (world wide long term=30 ) 30 ml Stability: Pack size: Efficacy Patient ompliance Route of admin.: Release type: Form: Biopereformance: Subjective properties: D. eriani Meet MINITAB, Milano 2/04/206 Safety Market needs 23
24 Smell Viscosity Assay Impurities level Stratum corneum permeation D. eriani Meet MINITAB, Milano 2/04/206 PEG peroxyde level Polymeric thickener Solvents API ontainer closure system Filter mesh Mixing time Mixer speed Oxygen presence Spindle type Mixer filling volume RITIAL QUATY ATTRIBUTES Material attributes and process parameters Spraying Spreading 24
25 Mixing speed (rpm) VOLUME (l) NITROGEN (bar) SPINDLE TYPE PEROX PEG (PPM) MIX TIME (h) FILTER RE SIZE (µm) BASE SMIT LEVELS Mixing speed VOLUME SPINDLE PEROX PEG NITROGEN MIX TIME FILTER MES RUN # D. eriani Meet MINITAB, Milano 2/04/206 25
26 Assay + impurities level 2 weeks 3 weeks month 2 months 3 months X X X X X 60 X X 40 /75% R Storage cond. Time week D. eriani Meet MINITAB, Milano 2/04/206 26
27 Main Effects Plot for Means Data Means VELO VOLUME PEG 0.60 Mean of Means SPINDLE 2 T MIX 2 FILTRO D. eriani Meet MINITAB, Milano 2/04/
28 VOLUME SPINDLE SPEED Level - Delta Rank D. eriani Meet MINITAB, Milano 2/04/206 PEG NITROGEN Response Table for Means Linear Model Analysis: factors ranking MIX TIME FILTER
29 EXLUDED PARAMETERS Estimated Model oefficients for Means ase study 4/6/205 NITROGEN, SPEED, SPINDLE P tail ( =0.05) mix speed volume spindle nitrogen mix time filter PEG NITROGEN, SPEED NITROGEN, SPEED, SPINDLE, MIX TIME Term oef onstant VOLUME PEG PEROX FILTER S = D. eriani Meet MINITAB, Milano 2/04/206 SE oef R-Sq = 00.0% T P R-Sq(adj) = 00.0% 29
30 Main Effects Plot for Means Data Means V E LO V O LU M E A ZO TO 2 TE M P O M IX 0.2 PEG F ILTRO 0.4 4/6/205 2 Mean of Means ase study 0.0 S P IN D LE D. eriani Meet MINITAB, Milano 2/04/206 30
31 SPEED VOLUME SPINDLE PEG NITROGEN MIX TIME FILTER Level - Delta Rank Response Table for Means Linear Model Analysis: factors ranking D. eriani Meet MINITAB, Milano 2/04/206 3
32 EXLUDED PARAMETERS SPEED, VOLUME, SPINDLE P tail ( =0.05) mix speed volume spindle nitrogen mix time filter PEG SPEED, VOLUME NITROGEN, SPEED, SPINDLE, MIX TIME Estimated Model oefficients for Means Term onstant PEG PEROX MIX TIME FILTER oef S = SE oef R-Sq = 00.0% D. eriani Meet MINITAB, Milano 2/04/206 T P R-Sq(adj) = 00.0% 32
33 a content in peroxides in raw material 2 ppm is mandatory PEG supplier choice based on raw material quality PEG container/closure and holding time from opening study (on going) PEG peroxides level is critical to product quality and safety D. eriani Meet MINITAB, Milano 2/04/206 33
34 Design space: spindle type doesn t matter Design space: nitrogen pressure in vessel between 0 and 2 bars Design space: mixer speed between 200 and 400 rpm D. eriani Meet MINITAB, Milano 2/04/206 34
35 Design space: mixer filling volume between nominal and 75% of nominal Design space: mix time between 4,5 and 8 h Design space: filter pore size between 0 and 00 µm D. eriani Meet MINITAB, Milano 2/04/206 35
36 Technology transfer and scale up process Process validation PAT implementation for real time release D. eriani Meet MINITAB, Milano 2/04/206 36
37 Pharmaceutical development steps Quality by design and Design Space are.. a powerful approach to obtain excellent medicines for the patients a chance to improve employees process awareness a stimulus to innovation and intellectual property D. eriani Meet MINITAB, Milano 2/04/206 37
38 D. eriani Meet MINITAB, Milano 2/04/206 WILAM EDWARDS DING 38
39 D. eriani Meet MINITAB, Milano 2/04/206 DANIELA ERIANI EAD, DEVELOPMENT LABORATORY LUGANO 39
Importance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
More informationChallenges of Implementation of ICH Q 8
Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated
More informationQuality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development
Innovate Development Create value Quality by Correct definition of QbD and its relation to product and process development Dr John Loveluck 42 Technology Ltd +44 1480 302700 john.loveluck@42technology.com
More informationQuality by Design, Clinical Relevance & Lifecycle Considerations
Quality by Design, Clinical Relevance & Lifecycle Considerations Robert Iser Acting Director Office of Process & Facilities / OPQ / CDER IFPAC 2016 1 FDA Quality Related Guidance and Initiatives Initiatives
More informationQ8 and Q8 annex An industry Perspective
Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference
More informationSTRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN
STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN CHRISTOPHER J POTTER ISPE ADVISOR AND CMC CONSULTANT 1 AGENDA Background ICH Guidelines Terms and Definitions Supporting Information ISPE publications
More informationQbD Application in Japan: PMDA Perspective
CMC Strategy Forum Japan 2013 Hotel Okura, Tokyo, Japan, December 9 10, 2013 QbD Application in Japan: PMDA Perspective Yasuhiro Kishioka, PhD. Reviewer Office of Cellular and Tissue based Products Pharmaceuticals
More informationPMDA perspective on Quality by Design for pharmaceutical products
PMDA perspective on Quality by Design for pharmaceutical products Junichi Fukuchi, Ph.D. Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA) Annual conference
More informationQuality by Design and OINDP. Today s Presentation
Quality by Design and OINDP Setting the Stage John C Berridge IPAC-RS September 2008 Today s Presentation QbD definition Setting the stage from an ICH perspective Future Opportunities 2 QbD Definition
More informationAnalytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective
Analytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective Dr. Øyvind Holte Norwegian Medicines Agency EMA PAT team/ EDQM PAT working party 15 October, 2014, Heidelberg
More informationImplementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
More informationValue Paper. Are you PAT and QbD Ready? Get up to speed
Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more
More informationICH Q8, 9 & 10 and the Impact on the QP
1 ICH Q8, 9 & 10 and the Impact on the QP Peter H. Gough David Begg Associates phg@david-begg-associates.com 2 A New Approach to Regulation Approach to the regulation of pharmaceuticals is undergoing a
More informationClaus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team
Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team
More informationQUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
VICH GL 45 (QUALITY) BRACKETING AND MATRIXING April 2010 For Implementation at Step 7 QUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
More informationQuality Risk Management
Quality Risk Management Iron Chef Edition Keith D. Gibbs kage and sui generis Ninja Project Management My story shapes my perspective Bachelor of Science work in Earth Science with focus on Hydrogeology.
More informationJUST SCRATCHING THE SERVICE
CONTRACT MANUFACTURING, PACKAGING & NEW EQUIPMENT TECHNOLOGY FOR THE BIOPHARM/PHARMACEUTICAL INDUSTRY OFFICIAL MEDIA SPONSOR OF W W W. P H A R M P R O. C O M V O L U M E 3 0, N U M B E R 4 M AY 2 0 1 5
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,
More informationCDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
More informationFrom API to Formulated Product
From API to Formulated Product Jean-Marie Geoffroy, PhD Director, Product Development Takeda Global Research & Development 675 N Field Drive Lake Forest, IL 60045 jean-marie.geoffroy@tgrd.com Acknowledgments
More informationImpact of ICH Q9 and the application of Risk Management
Safeguarding public health Impact of ICH Q9 and the application of Risk Management An inspector s perspective on the impact on inspectional approaches and expectations Ian Thrussell Strategy and Development
More informationCMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.
CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment
More informationPharmaceutical Manufacturing and Engineering Catalog Excerpt
Pharmaceutical Manufacturing and Engineering Catalog Excerpt PME 530 Introduction to Pharmaceutical Manufacturing Pharmaceutical manufacturing is vital to the success of the technical operations of a pharmaceutical
More informationTechnology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems
Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems A robust and secure manufactured product is the desired end result for pharmaceutical companies. Scale-up and
More informationThe Changing Face of Product and Process Development in the QbD Era. James Kraunsoe AstraZeneca Product Development UK/US
The Changing Face of Product and Process Development in the QbD Era James Kraunsoe AstraZeneca Product Development UK/US Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationOSIsoft. Users Conference 2013
OSIsoft. Users Conference 2013 Pharmaceutical and Life Sciences: Towards a Recipe Driven Company and the Critical Role of the Real Time Infrastructure Continuous Process Verification By: Martin Browning,
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Plenary Session Dr Moheb M. Nasr
More informationPHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW
PHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW Available online at www.ijdra.com REVIEW ARTICLE Sharma S*, Bodla R.B., Shweta S, Pathak D.P. Delhi Institute of Pharmaceutical Sciences and Research,
More informationMAH Responsibilities including the Management of CMOs. QP Forum Workshop. Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals
MAH Responsibilities including the Management of CMOs QP Forum 2017 - Workshop Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals 25 th April 2017 Alexion Pharmaceuticals in Ireland A
More informationTerrence Tougas. Dennis Sandell
Terrence Tougas Boehringer Ingeheim, Ridgefield, CT Dennis Sandell S5 Consulting, Lund, Sweden (c) 2011 Sandell & Tougas 1 Transforming the general concept of Quality into objective, well defined and actionable
More informationALL RAW MATERIALS ARE NOT CREATED EQUAL.
ALL RAW MATERIALS ARE NOT CREATED EQUAL. Meet Diagnostics Elite DIAGNOSTIC SOLUTIONS Reimagine what s possible. REDUCE RISK. INCREASE CONSISTENCY. The Diagnostics Elite program is more than just a set
More informationFDA s Evolving Approach to Pharmaceutical Quality
FDA s Evolving Approach to Pharmaceutical Quality Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 10th Annual FDA Inspections Summit Nov.
More informationSymposium on Continuous Manufacturing of Pharmaceuticals Notes
1 2012 11 13 Symposium on Continuous Manufacturing of Pharmaceuticals Notes These are notes from the first open meeting regarding Novartis- MIT Center for Continuous Manufacturing (CCM). The meeting is
More informationAnalytical Development Labs
Analytical Development Labs S-Matrix ADL Purdue Technology Center 5225 Exploration Drive Suite S-2357 Indianapolis, IN 46241 USA URL: www.smatrix.com Overview Major Pharmaceutical companies worldwide use
More informationLeader in Pharmaceutical Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation
More informationHow Process Models can Facilitate Quality Risk Management for Emerging Technologies
How Process Models can Facilitate Quality Risk Management for Emerging Technologies Thomas O Connor, Ph.D. FDA-AIChE Workshop on Adopting Continuous Manufacturing North Bethesda, MD March 2 th, 2016 2
More informationAssociation. Innovation in Medicines PDA: A Global. and Manufacturing. David Tainsh, GSK Keith Pugh, MHRA
Innovation in Medicines PDA: A Global and Manufacturing Association David Tainsh, GSK Keith Pugh, MHRA Joint Regulators/Industry QbD Workshop 28-29 January 2014 London, UK Introduction Current State We
More informationOffice of Pharmaceutical Quality Key Quality Initiatives
Office of Pharmaceutical Quality Key Quality Initiatives Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality Center for Drug Evaluation and Research
More informationTranslational scientist competency profile
C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective
More informationEU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
More informationGlobal Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel
Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation Jane Weitzel mljweitzel@msn.com Jane Weitzel Biosketch Jane Weitzel has been working in analytical chemistry for over
More informationUSP Research & Innovation Program
USP Research & Innovation Program Ding Ming, Ph.D. Vice president, Research & Innovation United States Pharmacopeial Convention (USP) October 13, 2016 USP Programs and Products Impact Millions Worldwide
More informationOffice of Pharmaceutical Quality: Why, What, and How?
Office of Pharmaceutical Quality: Why, What, and How? Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research NIPTE Annual Scientific Conference
More informationWaterless dyeing process for DryDye fabrics
Waterless dyeing process for DryDye fabrics This process is used in producing functional knitted fabrics with the brand name DryDye fabrics, this method uses an exclusive waterless dyeing process that
More informationRequirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, Dr. Helmut Rockstroh
Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, 2015 Dr. Helmut Rockstroh Overview Introduction - Scope Pharmacopoeial + HA Positions Examples / Case Studies Discussion 2 Introduction:
More informationHow CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry
How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry Moderator: Lawrence Yu Speakers: Thomas O Connor & Sharmista Chatterjee Emerging Technology: A Key Enabler for Modernizing
More informationICH Q-IWG Integrated Training Programme
Implementation of ICH Q8, Q9, Q10 ICH Q-IWG Integrated Training Programme International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer
More informationInternational Journal of Pharma and Bio Sciences PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY ABSTRACT
Research Article Analytical Chemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY SARAVANA KUMAR.V
More informationManufacture of medicinal products in Italy: challenges for the Italian Medicines Agency
Manufacture of medicinal products in Italy: challenges for the Italian Medicines Agency Isabella Marta Coordinator Inspections and Certification Dept. Head Manufacturing Authorization Office Italian Medicines
More informationBuilding Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology
Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology Sau (Larry) Lee, Ph.D. Associate Director for Science Office of Pharmaceutical
More informationHow can value be measured and assessed?
Dávid Dankó, PhD, MSc Corvinus University of Budapest Institute of Management david.danko at uni-corvinus.hu How can value be measured and assessed? ISPOR 5 th Asia-Pacific Conference, Taipei, 2 September
More informationWHITE PAPER FACILITY FOCUS: GMP Facility Modernization. By: David M. Marks, P.E.
WHITE PAPER FACILITY FOCUS: GMP Facility Modernization By: David M. Marks, P.E. July 2017 Introduction In recent years, intensified industry competition and cost pressures have renewed interest in modernizing
More informationModel Based Design Of Medical Devices
Model Based Design Of Medical Devices A Tata Elxsi Perspective Tata Elxsi s Solutions - Medical Electronics Abstract Modeling and Simulation (M&S) is an important tool that may be employed in the end-to-end
More informationInnovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series
CAMO European Pharmaceutical Seminars Jan/Feb 2009 Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series The Increasing Need of Multivariate Analysis for Process Understanding
More informationIntroduction. Methods: Spherical Granulation. Shawn Engels, Vector Corporation
DISCUSSION OF PROCESSES WHICH UTILIZE CONICAL ROTOR TECHNOLOGY (SPHERONIZATION OR SPHERICAL GRANULATION, POWDER LAYERING OF ACTIVES OR POLYMERS, CONVENTIONAL SOLUTION/SUSPENSION APPLICATION OF ACTIVES
More informationThe International Pharmacopoeia Overview
The International Pharmacopoeia Overview Prepared by Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines The International Pharmacopoeia P Content & Scope WHO Expert Committee on
More informationICH Q8 / ICH Q11 Training Course
ICH Q8 / ICH Q11 Training Course From QbD to Process Validation Speakers: Dr Thomas Hille LTS Lohmann Therapie- Systeme AG Dr Øyvind Holte Norwegian Medicines Agency, EDQM PAT working party/ EMA PAT team
More informationThe Influence of Coating System Type on Acetaminophen Release from Ethylcellulose Barrier Membrane Coated Multiparticulates
ETHOCEL / Surelease Application Data Premium Ethylcellulose Polymers / Aqueous Ethylcellulose Disperson The Influence of Coating System Type on Acetaminophen Release from Ethylcellulose Barrier Membrane
More informationWHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future. By: Hite Baker
WHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future By: Hite Baker August 2017 Introduction This Facility Focus Survey Report explores how to design sterile
More informationICH Q7 - API. Presented by Ashley Isbel 4 July, 2016
ICH Q7 - API Presented by Ashley Isbel 4 July, 2016 ICH Q7 ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (November 2000) Adopted or referenced by: PIC/S in 2007 - Guide
More informationPDA 71 Years of Connecting People, Science and Regulation
PDA 71 Years of Connecting People, Science and Regulation 1 I m happy to be here. Bom Dia. Estou feliz por estar aqui. Richard M. Johnson PDA President & CEO since 2009 38 years experience in US and International
More informationBeware the non-critical excipient
Beware the non-critical excipient Dr Brian A Carlin Director Open Innovation, Chair IPEC QbD Committee brian.carlin@fmc.com ExcipientFest 2012 1 Understand your raw materials http://www.ich.org/uploads/media/q-iwg_web_basic_training.pdf
More informationFeedback EMEA / Industry Discussion
Feedback EMEA / Industry Discussion Eli Lilly & Co Ltd Case Study: Use of In-Line Near-Infrared Spectroscopy to Monitor Segregation of a Pharmaceutical Powder Blend in a Tablet Press Martin Diller PhD,
More informationLIGHTHOUSE. The Science of Pharmaceutical Manufacturing
The Science of Pharmaceutical Manufacturing The Power of headspace inspection insight into the process. On the other hand, rapid non-destructive headspace analysis from is a powerful analytical tool for
More information325 to 500 GHz Vector Network Analyzer System
325 to 500 GHz Vector Network Analyzer System By Chuck Oleson, Tony Denning and Yuenie Lau OML, Inc. Abstract - This paper describes a novel and compact WR-02.2 millimeter wave frequency extension transmission/reflection
More informationHealthTech: What does it mean for compliance?
HealthTech: What does it mean for compliance? May 2018 Agenda 11:15 AM 11:30 AM Introduction Kathleen Meriwether, Americas Leader - Life Sciences Fraud Investigation & Dispute Services, EY 11:30 AM 12:15
More informationPRODUCT PROFILE ELECTROLOY NO CLEAN LEAD FREE PASTE
PRODUCT PROFILE ELECTROLOY NO CLEAN LEAD FREE PASTE Product Name Product Code #515 LEAD FREE PASTE Sn99.0/Ag0.3/Cu0.7 EMCO#515-315P DOC CATEGORY: 3 PF EMCO#515-315P 14062010 REV.B Page 1 of 5 PRODUCT DESCRIPTION
More informationGlobal GMP Harmonisation A Japanese Perspective
Global GMP Harmonisation A Japanese Perspective Yukio Hiyama, Ph.D. Chief, Third Section, Division of Drugs, National Institute of Health Sciences, The Ministry of Health Labour and Welfare, JAPAN ISPE
More informationQuality Regulation under Revised Pharmaceutical Affair Law
Quality Regulation under Revised Pharmaceutical Affair Law Yukio Hiyama, Ph.D. Division of Drugs, National Institute of Health Sciences, the Ministry of Health, Labour and Welfare, Japan E mail hiyama@nihs.go.jp
More informationClaudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group
FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel
More informationPharmaceutical Process Development
Announcing the following Seminar to be conducted by IVEPE-SEV Pharmaceutical Process Development Factors in Scale-Up, Process Validation and Regulatory Considerations Course Topics Include: Solid Dosage
More informationEmbracing Quality by Design. Applying QbD concepts can help CMOs create value
Embracing Quality by Design Applying QbD concepts can help CMOs create value By Russ Somma, Ph.D. and Andrew A. Signore, PE, PMP-DBIA, CPIP SommaTech, LLC Integrated Project Services (IPS) THE PHARMACEUTICAL
More informationInter-Association Task Force
Inter-Association Task Force Presentation to EMA Workshop Prevention of Drug Shortages Based on Quality and Manufacturing Issues 9 th October 2015 1 Topics for Today Background and history of task force
More informationA BALANCING ACT: STREAMLINING METHOD TRANSFERS WITHOUT COMPROMISING COMPLIANCE OR SCIENCE JULIE FROST SENIOR SPECIALIST, QUALITY CONTROL
A BALANCING ACT: STREAMLINING METHOD TRANSFERS WITHOUT COMPROMISING COMPLIANCE OR SCIENCE JULIE FROST SENIOR SPECIALIST, QUALITY CONTROL PRESENTATION OUTLINE Introduction The Improved Comparative Study
More informationICH Q10 Pharmaceutical Quality System
Safeguarding public health ICH Q10 Pharmaceutical Quality System An EU Regulator s Perspective Presentation overview Why does Q10 exist and what were the desired outcomes Content of the Q10 step 2 document
More informationSpectrum 400. FT-IR and FT-NIR Spectrometer. There is only one answer.
Spectrum 400 FT-IR and FT-NIR Spectrometer There is only one answer. The latest innovation in PerkinElmer s long history of IR technology leadership For over 60 years, PerkinElmer has been the world leader
More informationThe Transition to Model-Based Drug Development. Phase 1: Formalizing the Pharmacometric Process
1780 Wehrle Drive Suite 110 Buffalo, New York 14221 716.633.3463 cognigencorp.com The Transition to Model-Based Drug Development Phase 1: Formalizing the Pharmacometric Process By Thaddeus H. Grasela,
More informationSection heading. Strapline sub-heading
Section heading Strapline sub-heading Smart every time NextPharma stands out as your pharmaceutical development and manufacturing partner with fast, flexible and tailored solutions for markets worldwide
More informationEnforcement Regulations of the Pharmaceutical Affairs Law
Enforcement Regulations of the Pharmaceutical Affairs Law The Enforcement Regulations of the Pharmaceutical Affairs Law ( PAL ) shall be amended, in part, as follows: Article 24 (Product approval application
More informationGSK s Development of Novel Oral Delivery Technologies Perspectives
GSK s Development of Novel Oral Delivery Technologies Perspectives Mark Wilson Director, PTS, R&D GlaxoSmithKline Pharmaceuticals GSK Established a Technology Incubator To Develop Drug Delivery Systems
More informationConsiderations for Leachables and Extractables in a Quality by Design Environment
IPAC-RS 2006 Conference Inhalation and Nasal Drugs: The Regulatory Landscape Considerations for Leachables and Extractables in a Quality by Design Environment Daniel L. Norwood, Ph.D. Director Physical
More informationpeace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
More informationTowards malaria elimination: ADB-supported work at Myanmar FDA
Towards malaria elimination: ADB-supported work at Myanmar FDA Valerio Reggi 25 January 2018 Disclaimer: The views expressed in this paper/presentation are the views of the author and do not necessarily
More informationQbD/PAT Implementation: The Road to RTR From Science to Compliance
Quality by Design China 2013 April 17-18, 2013 Shanghai, China Pedro Hernandez, PhD 何盼多博士 Senior Director Quality Assurance - China http://www.frontagelab.com pedrohernandez@frontagelab.com.cn Background
More information4 Oct, 2018 RefComm Valencia 1
4 Oct, 2018 RefComm Valencia 1 SRU Thermal Reactor Chemistry & Design Roelof ten Hooven Area Sales Manager 4 Oct, 2018 RefComm Valencia 2 Company Profile Engineering company specialized in process combustion
More informationProcess Analytical Technology (PAT): A Real Time Quality Assurance
Review Article Process Analytical Technology (PAT): A Real Time Quality Assurance Punita Raj, N. Vishal Gupta* Pharmaceutical Quality Assurance group, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara
More informationProgress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003
Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared
More informationThe Process Analytical Technology Initiative: PAT and the Pharmacopeias
The Process Analytical Technology Initiative: PAT and the Pharmacopeias Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science CDER, FDA EDQM Spring Conference, Cannes, 3-43 4 May 2004
More informationTECH TRANSFER University Joins Industry. Maite Aguado Pharmaceutical Technology PL Synthon Hispania
TECH TRANSFER University Joins Industry Maite Aguado Pharmaceutical Technology PL Synthon Hispania About me.. - Chemical Degree (UAB) / Master In Pharmaceuticals and Related Products(IUCT) / Master In
More informationPRIMAL HG-415 Pure Acrylic Binder
Technical Data Sheet PRIMAL HG-415 Pure Acrylic Binder For Gloss Paints With Improved Application Properties Product Description Regional Product Availability PRIMAL HG-415 Acrylic Binder is a pure acrylic
More informationDetection and Characterization of Acoustic Signals from a Granulation Process
Detection and Characterization of Acoustic Signals from a Granulation Process Yogesh Gupta*, Terence O Brien*, Ruiyao Gao* *ITT Dublin, Ireland. Yogeshgupta@ieee.org, Terence.Obrien@ittdublin.ie, Ruiyao.Gao@ittdublin.ie
More informationOrthocryl LC. the acrylic you've always dreamed of for your appliances. Stefan Kehlbacher
62 Spectrum dialogue Vol. 14 No. 2 February 2015 Orthocryl LC the acrylic you've always dreamed of for your appliances Stefan Kehlbacher Cold-curing acrylics have been used and processed in orthodontics
More informationProfiling of Volatile Organic Compounds in Milk and Orange Juice Using Headspace Analysis
Profiling of Volatile Organic Compounds in Milk and Orange Juice Using Headspace Analysis HT3 Application Note Introduction Volatile organic compounds, VOCs, present in liquid food products play a very
More informationTimescales for Change A Look at Innovation in the Pharmaceutical Industry
Timescales for Change A Look at Innovation in the Pharmaceutical Industry 3rd FDA/PQRI Conference on Advancing Product Quality 23 Mar 2017 Robert F. Meyer, Ph.D. Global Pharmaceutical Commercialization
More informationQUALITY REQUIREMENTS FOR ARTEMISININ AS A STARTING MATERIAL IN THE PRODUCTION OF ANTIMALARIAL ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)
August 2010 RESTRICTED QUALITY REQUIREMENTS FOR ARTEMISININ AS A STARTING MATERIAL IN THE PRODUCTION OF ANTIMALARIAL ACTIVE PHARMACEUTICAL INGREDIENTS (APIs) Please address comments on this proposal, by
More informationHealth Technology Assessment of innovative medical devices
Health Technology Assessment of innovative medical devices Dr. Iñaki Gutiérrez-Ibarluzea Knowledge Manager Vicepresident of EuroScan International Network Osteba, Basque Office for HTA Ministry for Health
More informationPSE Technology Corporation
PSE Technology Corporation SPECIFICATION FOR APPROVAL CUSTOMER NOMINAL FREQUENCY 32.768000 KHz PRODUCT TYPE SPEC. NO. ( P/N ) TYPE KJ 2.5x2.0 SEAM SEALED CRYSTAL CLOCK OSCILLATOR CUSTOMER P/N ISSUE DATE
More information(Fig.) JPMA Industry Vision 2025
2. JPMA Industry Vision 2025 Against the background of the changing environment surrounding the pharmaceutical industry and the future predictions *1, we prepared JPMA Industry Vision 2025 Bringing Innovation
More informationThe Best Way to Get the Right Answers... is in a Flash
FlashQuant Workstation The Best Way to Get the Right Answers... is in a Flash FlashQuant Workstation: Integrating MALDI Speed with Triple Quad Selectivity 5.03E+02 0.011 1.40E+03 2.680 5.26E+02 0.011 1.30E+03
More information